RarePlex PD-L1 (Programmed Death Ligand) CTC Panel Kit
Tumors can induce immune suppression by modulating immune responses via immune checkpoint pathways that rely on the programmed cell death protein 1 (PD-1) binding to its ligand, programmed death ligand 1 (PD-L1).1 The interaction of PD-L1 on tumor cells with its receptor PD-1 on activated T cells, is one of the main pathways exploited by cancer cells for immune evasion. PD-L1 expression has been observed in a wide variety of tumors and has been associated with poor clinical outcomes.2
The binding of PD-L1 to PD-1 on activated T cells also causes T-cell exhaustion2, which is characterized by the stepwise and progressive loss of T-cell functions.3 Blocking the binding of PD-L1 to PD-1 with an immune checkpoint inhibitor drug (anti-PD-L1 or anti-PD-1) can re-activate the T cells to kill tumor cells once again.
How Rarecyte’s Programmed Death Ligand CTC Assay Works to Detect Cancer Cells
RareCyte’s PD-L1 circulating tumor cell (CTC) assay provides highly accurate, repeatable, and precise results for circulating tumor cell counting and measuring PD-L1 biomarker expression, and is suitable for use in large, multi-center clinical trials. The assay includes processing blood to slides with the AccuCyte® Sample Preparation System followed by staining with the RarePlex 0912-VB PD-L1 CTC Panel Kit and imaging on a CyteFinder® Instrument. Machine learning enabled analysis and scoring maximizes reviewer concordance.
This PD-L1 assay is deployed on RareCyte’s circulating tumor cell analysis platform with:
- Simple processing of blood to slides for sample banking
- Convenient pause points in workflow enable sample control and transport
- Flexibility in sample handling – processing and analysis may be performed at the same site or at a separate clinical research laboratory when desired
- Extensive validation and highly automated process yield accurate and highly reproducible results
- Worldwide network of contract research organizations (CROs) to support global clinical trials
Additional resources for the RarePlex PD-L1 Panel KitDownload the specification sheet →
- Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313-1325. doi:10.1002/jcp.27172
- Jiang Y, Chen M, Nie H, Yuan Y. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother. 2019;15(5):1111-1122. doi:10.1080/21645515.2019.1571892Liu J, Chen Z, Li Y, Zhao W, Wu J and Zhang Z (2021) PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Front. Pharmacol. 12:731798. doi: 10.3389/fphar.2021.731798
- Wang X, Teng F, Kong L, Yu J. PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther. 2016;9:5023-5039. Published 2016 Aug 12. doi:10.2147/OTT.S105862
Working with the RarePlex® Developer Kit
Presented by Edward Lo, Ph.D., Scientist, Assay Development Lead
Developer technology from RareCyte enables you to add up to two custom biomarkers to your CTC assay. This 5 minute video will walk you through each step of the Developer process and provide examples of completed assays.